First Tracks Biotherapeutics Inc (TRAX)

$43.88 +0.28 (0.64%)
Market Cap 1.56B
Revenue (ttm) 0.00
Net Income (ttm) -163.71M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 724,600
Avg Vol 806,524
Day's Range N/A - N/A
Shares Out 35.73M
Stochastic %K 20%
Beta N/A
Analysts Strong Sell
Price Target $63.38

Company Profile

First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifical...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 362 6295
Address:
10770 Wateridge Circle, Suite 210, San Diego, United States
IN0V8
IN0V8 Aug. 18 at 4:16 PM
$TRAX JP Morgan raises target price to $65 from $30
0 · Reply
MikeyNJ
MikeyNJ Aug. 13 at 12:09 PM
$TRAX Piper Sandler raises price target to $95.
0 · Reply
IN0V8
IN0V8 Aug. 10 at 5:54 PM
$TRAX Opportunity UBS raises target price to $65 from $45
0 · Reply
MikeyNJ
MikeyNJ Aug. 10 at 3:19 PM
$TRAX UBS ups price target from $45 to $65.
0 · Reply
StockBraker
StockBraker Aug. 5 at 2:13 PM
$TRAX $ANAB Need to break through the $105 combined price ceiling. I hate this overhang from the Tesaro lawsuit. Legal processes move too slow.
0 · Reply
Anonymous10000
Anonymous10000 Aug. 4 at 1:25 AM
$TRAX come to $SLS. We have an upcoming catalyst! https://seekingalpha.com/article/4922043-sellas-life-sciences-strong-buyimminent-catalyst-dual-platform-pipeline-and-a-market-that-hasnt-caught-up
1 · Reply
StockBraker
StockBraker Jul. 30 at 2:03 PM
$TRAX Got 1,000 shares you would like to sell by mid-October for $60? Sell a covered call and collect between $2,000-6,500 today in premiums and $60,000 on the expiration date if the price gets and stays above $60.
0 · Reply
StockBraker
StockBraker Jul. 30 at 1:58 PM
$TRAX
0 · Reply
Jt11111
Jt11111 Jul. 29 at 6:22 PM
$TRAX $ANAB solid Jemperil sales from gsk —$320MM keep ANAB royalty on track and this is a steal at $50. 1. H1 2026 Actual Sales (First Half) Q1 2026: £232 million ($313 million USD) Q2 2026: £248 million ($320 million USD) Total H1 2026: £480 million GBP (~$620 million USD)
1 · Reply
StockBraker
StockBraker Jul. 27 at 10:59 PM
$TRAX I need to keep an eye out for more of his trashcan posts.
0 · Reply
Latest News on TRAX
First Tracks Biotherapeutics reports Q2 EPS (95c), consensus (80c)

2026-08-17T08:42:57.000Z - 2 days ago

First Tracks Biotherapeutics reports Q2 EPS (95c), consensus (80c)

First Tracks Biotherapeutics price target raised to $65 from $48 at Barclays

2026-08-17T08:31:00.000Z - 2 days ago

First Tracks Biotherapeutics price target raised to $65 from $48 at Barclays

First Tracks price target raised to $57 from $44 at H.C. Wainwright

2026-08-17T08:26:38.000Z - 2 days ago

First Tracks price target raised to $57 from $44 at H.C. Wainwright

First Tracks Biotherapeutics price target raised to $95 from $54 at Piper Sandler

2026-08-17T08:14:10.000Z - 2 days ago

First Tracks Biotherapeutics price target raised to $95 from $54 at Piper Sandler

First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update

Aug 12, 2026, 4:15 PM EDT - 6 days ago

First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update

First Tracks Biotherapeutics Earnings release: Q2 2026

Aug 12, 2026, 4:00 PM EDT - 6 days ago

First Tracks Biotherapeutics Earnings release: Q2 2026

First Tracks Biotherapeutics Quarterly report: Q2 2026

Aug 12, 2026, 4:00 PM EDT - 6 days ago

First Tracks Biotherapeutics Quarterly report: Q2 2026

First Tracks Biotherapeutics management to meet with Piper Sandler

2026-08-10T19:55:55.000Z - 8 days ago

First Tracks Biotherapeutics management to meet with Piper Sandler

First Tracks Biotherapeutics price target raised to $65 from $45 at UBS

2026-08-10T13:20:33.000Z - 8 days ago

First Tracks Biotherapeutics price target raised to $65 from $45 at UBS

First Tracks Biotherapeutics price target raised to $60 from $30 at Wedbush

2026-07-28T12:01:37.000Z - 21 days ago

First Tracks Biotherapeutics price target raised to $60 from $30 at Wedbush

ARGX FBRX TEVA

First Tracks Biotherapeutics price target raised to $55 from $30 at Wells Fargo

2026-07-28T10:15:32.000Z - 22 days ago

First Tracks Biotherapeutics price target raised to $55 from $30 at Wells Fargo

FBRX

First Tracks Biotherapeutics price target raised to $48 from $40 at Barclays

2026-07-21T10:20:10.000Z - 4 weeks ago

First Tracks Biotherapeutics price target raised to $48 from $40 at Barclays

First Tracks Biotherapeutics price target raised to $44 from $30 at H.C. Wainwright

2026-07-10T10:05:09.000Z - 5 weeks ago

First Tracks Biotherapeutics price target raised to $44 from $30 at H.C. Wainwright

FBRX

First Tracks Biotherapeutics initiated with an Overweight at Wells Fargo

2026-06-08T09:00:08.000Z - 2 months ago

First Tracks Biotherapeutics initiated with an Overweight at Wells Fargo

First Tracks Biotherapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 12:15 PM EDT - 2 months ago

First Tracks Biotherapeutics Transcript: Jefferies Global Healthcare Conference 2026

First Tracks Biotherapeutics Slides: FY 2026

Jun 3, 2026, 12:15 PM EDT - 2 months ago

First Tracks Biotherapeutics Slides: FY 2026

First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences

May 21, 2026, 4:15 PM EDT - 3 months ago

First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences

First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

May 14, 2026, 4:15 PM EDT - 3 months ago

First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

First Tracks Biotherapeutics Earnings release: Q1 2026

May 14, 2026, 7:00 AM EDT - 3 months ago

First Tracks Biotherapeutics Earnings release: Q1 2026

First Tracks Biotherapeutics Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 3 months ago

First Tracks Biotherapeutics Quarterly report: Q1 2026

First Tracks Biotherapeutics Slides: Corporate presentation

May 14, 2026, 7:00 AM EDT - 3 months ago

First Tracks Biotherapeutics Slides: Corporate presentation

First Tracks Biotherapeutics files to sell 10.5M shares of common for holders

2026-05-08T22:52:09.000Z - 3 months ago

First Tracks Biotherapeutics files to sell 10.5M shares of common for holders

First Tracks Biotherapeutics Registration statement: Registration filing

May 8, 2026, 8:00 AM EDT - 3 months ago

First Tracks Biotherapeutics Registration statement: Registration filing

First Tracks Biotherapeutics initiated with an Overweight at Piper Sandler

2026-05-04T08:40:30.000Z - 3 months ago

First Tracks Biotherapeutics initiated with an Overweight at Piper Sandler

First Tracks Biotherapeutics initiated with a Buy at H.C. Wainwright

2026-04-28T10:10:15.000Z - 4 months ago

First Tracks Biotherapeutics initiated with a Buy at H.C. Wainwright

First Tracks Biotherapeutics initiated with an Outperform at Leerink

2026-04-24T11:36:50.000Z - 4 months ago

First Tracks Biotherapeutics initiated with an Outperform at Leerink

ANAB

First Tracks Biotherapeutics initiated with an Overweight at Barclays

2026-04-23T12:11:58.000Z - 4 months ago

First Tracks Biotherapeutics initiated with an Overweight at Barclays

First Tracks Biotherapeutics initiated with an Overweight at JPMorgan

2026-04-23T12:11:27.000Z - 4 months ago

First Tracks Biotherapeutics initiated with an Overweight at JPMorgan

First Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases

Apr 20, 2026, 9:15 AM EDT - 4 months ago

First Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases

IN0V8
IN0V8 Aug. 18 at 4:16 PM
$TRAX JP Morgan raises target price to $65 from $30
0 · Reply
MikeyNJ
MikeyNJ Aug. 13 at 12:09 PM
$TRAX Piper Sandler raises price target to $95.
0 · Reply
IN0V8
IN0V8 Aug. 10 at 5:54 PM
$TRAX Opportunity UBS raises target price to $65 from $45
0 · Reply
MikeyNJ
MikeyNJ Aug. 10 at 3:19 PM
$TRAX UBS ups price target from $45 to $65.
0 · Reply
StockBraker
StockBraker Aug. 5 at 2:13 PM
$TRAX $ANAB Need to break through the $105 combined price ceiling. I hate this overhang from the Tesaro lawsuit. Legal processes move too slow.
0 · Reply
Anonymous10000
Anonymous10000 Aug. 4 at 1:25 AM
$TRAX come to $SLS. We have an upcoming catalyst! https://seekingalpha.com/article/4922043-sellas-life-sciences-strong-buyimminent-catalyst-dual-platform-pipeline-and-a-market-that-hasnt-caught-up
1 · Reply
StockBraker
StockBraker Jul. 30 at 2:03 PM
$TRAX Got 1,000 shares you would like to sell by mid-October for $60? Sell a covered call and collect between $2,000-6,500 today in premiums and $60,000 on the expiration date if the price gets and stays above $60.
0 · Reply
StockBraker
StockBraker Jul. 30 at 1:58 PM
$TRAX
0 · Reply
Jt11111
Jt11111 Jul. 29 at 6:22 PM
$TRAX $ANAB solid Jemperil sales from gsk —$320MM keep ANAB royalty on track and this is a steal at $50. 1. H1 2026 Actual Sales (First Half) Q1 2026: £232 million ($313 million USD) Q2 2026: £248 million ($320 million USD) Total H1 2026: £480 million GBP (~$620 million USD)
1 · Reply
StockBraker
StockBraker Jul. 27 at 10:59 PM
$TRAX I need to keep an eye out for more of his trashcan posts.
0 · Reply
STACKD0E
STACKD0E Jul. 27 at 5:07 PM
$JBS $GENI $TRAX $RNG ✨
0 · Reply
notreload_ai
notreload_ai Jul. 27 at 4:25 PM
H.C. Wainwright says $FBRX acquisition is positive for $TRAX because Forte’s drug competes with TRAX’s ANB033. The firm believes this could increase interest in First Tracks if clinical results are successful and keeps a Buy rating while reviewing its valuation.
0 · Reply
MikeyNJ
MikeyNJ Jul. 27 at 2:29 PM
$TRAX Wedbush raises price target to $60.
0 · Reply
Nickman18
Nickman18 Jul. 27 at 2:23 PM
$ANAB $TRAX I've owned since 2019 with a price average of 20.66 just wanted to brag quickly
1 · Reply
topstockalerts
topstockalerts Jul. 27 at 1:27 PM
Pre Market Top Gainers PT2 $ENTX $FBRX $JZXN $TRAX $GOSS
0 · Reply
Daytradingdude
Daytradingdude Jul. 27 at 12:22 PM
$DFNS $FBRX $LGHL $MTNB $TRAX
0 · Reply
topstockalerts
topstockalerts Jul. 27 at 12:22 PM
Pre Market Top Gainers $LGHL $MTNB $DFNS $FBRX $TRAX
0 · Reply
StockBraker
StockBraker Jul. 27 at 11:43 AM
$TRAX Thanks Argenx. Waiting before selling any more FirstTracks
0 · Reply
StockBraker
StockBraker Jul. 27 at 11:24 AM
$TRAX Forte Biosciences and AnaptysBio are connected as the two primary competitors developing therapies in the CD122 (IL-2/IL-15 receptor beta) space for autoimmune and inflammatory diseases. The connection became highly relevant following news that pharmaceutical giant Argenx agreed to acquire Forte Biosciences for $2.2 billion. This acquisition directly impacts the competitive landscape for AnaptysBio's spin-off assets. https://finance.yahoo.com/healthcare/articles/argenx-agrees-2-2-billion-104613226.html
0 · Reply
topstockalerts
topstockalerts Jul. 27 at 11:20 AM
Pre Market Top Gainers PT2 $TRAX $SXTC $VEEE $AIMD $TAOX
0 · Reply
StockBraker
StockBraker Jul. 27 at 11:14 AM
$TRAX Why are all the Stocktwits prices wrong this morning?
0 · Reply
DekmarTrades
DekmarTrades Jul. 27 at 11:08 AM
I see no news on $TRAX, but still the stock is up 40% and looking for new highs! Continued momentum from earlier July gains tied to positive read-through from competitor data (Forte Biosciences / FBRX Phase 1b vitiligo results validating the broader CD122 pathway).
0 · Reply